Bioventus Inc. provided earnings guidance for the twelve months ending December 31, 2023. For the period, the company expects net sales to be between $490 million to $505 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.6 USD | -3.78% |
|
-14.37% | +6.26% |
05-07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
05-07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.26% | 371M | |
+75.69% | 12.57B | |
+11.24% | 7.21B | |
-30.25% | 6.82B | |
+11.54% | 5.35B | |
-20.60% | 4.59B | |
+10.66% | 3.95B | |
-22.56% | 3.69B | |
-28.90% | 2.64B | |
+28.43% | 2.09B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Bioventus Inc. Provides Earnings Guidance for the Twelve Months Ending December 31, 2023